You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Relapsing-remitting multiple sclerosis

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsing Remitting Multiple Sclerosis Trial (PIPE-307 Dose A, PIPE-307 Dose B, Placebo)

Not yet recruiting
  • Relapsing Remitting Multiple Sclerosis
  • PIPE-307 Dose A
  • +2 more
  • (no location specified)
Oct 9, 2023

Relapsing-remitting Multiple Sclerosis Trial (CT-P53, US-Ocrevus, EU-Ocrevus)

Not yet recruiting
  • Relapsing-remitting Multiple Sclerosis
  • CT-P53
  • +2 more
  • (no location specified)
Jun 7, 2023

Multiple Sclerosis Trial in Montpellier (Magnetic Resonance Imaging, Blood withdrawal, Neuropsychological tests)

Not yet recruiting
  • Multiple Sclerosis
  • Magnetic Resonance Imaging
  • +2 more
  • Montpellier, France
    Neurology Department, Hopital Gui de Chauliac
Jul 18, 2023

Relapsing-Remitting Multiple Sclerosis (RRMS) Participants

Not yet recruiting
  • Relapsing-remitting Multiple Sclerosis (RRMS)
    • (no location specified)
    Apr 11, 2023

    Multiple Sclerosis Trial in Genova (7-day Fasting-Mimicking Diet (7-DAY FMD))

    Active, not recruiting
    • Multiple Sclerosis
    • 7-day Fasting-Mimicking Diet (7-DAY FMD)
    • Genova, Italy
      Ospedale San Martino
    Sep 8, 2023

    Assess New Participant's Perspectives Beyond Clinical Efficacy

    Not yet recruiting
    • Multiple Sclerosis, Relapsing-Remitting
      • (no location specified)
      Nov 7, 2023

      Multiple Sclerosis, Relapsing-Remitting Trial in Elazig (Reiki)

      Recruiting
      • Multiple Sclerosis, Relapsing-Remitting
      • Reiki
      • Elazıg, Turkey
        Firat University
      Nov 8, 2023

      Describe Switching FromFirst- or Second-line Disease Modifying

      Not yet recruiting
      • Multiple Sclerosis, Relapsing-Remitting
        • (no location specified)
        Dec 12, 2022

        Multiple Sclerosis, Relapsing-Remitting, Fatigue Trial (TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY], Placebo)

        Withdrawn
        • Multiple Sclerosis, Relapsing-Remitting
        • Fatigue
        • TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY]
        • Placebo
        • Boston, Massachusetts
          Massachusetts General Hospital
        Nov 14, 2022

        Multiple Sclerosis, Relapsing-Remitting Trial in Munich, Mainz, Münster (Vivomixx®, Conjugated linoleic acid (CLA/Tonalin® FFA

        Not yet recruiting
        • Multiple Sclerosis, Relapsing-Remitting
        • Vivomixx®
        • +3 more
        • Munich, Bavaria, Germany
        • +2 more
        Jun 15, 2023

        Multiple Sclerosis, Relapsing-Remitting Trial in La Jolla (Autologous hematopoietic stem cell transplantation,

        Recruiting
        • Multiple Sclerosis, Relapsing-Remitting
        • Autologous hematopoietic stem cell transplantation
        • +2 more
        • La Jolla, California
          Scripps Green Hospital
        Aug 16, 2022

        Bafiertam Treatment In Routine Clinical Practice

        Enrolling by invitation
        • Relapsing Remitting Multiple Sclerosis
        • Monomethyl Fumarate
        • West Hollywood, California
        • +1 more
        Aug 3, 2023

        Lesion Load and Location in Relation to Cognition, Fatigue and

        Completed
        • Relapsing Remitting Multiple Sclerosis
        • VolBrain, a fully automated platform to generate the volumetric data (lesion count, volume and location as well as different atrophy measures)
        • Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)
        • Assiut, Egypt
          Eman Khedr
        Oct 27, 2022

        Deficient T Regulatory Cell Function in Relapsing Remitting

        Recruiting
        • Relapse Remitting Multiple Sclerosis
          • Philadelphia, Pennsylvania
            Thomas Jefferson University
          Jun 13, 2022

          Generic Fingolimod in Relapsing-Remitting Multiple Sclerosis in

          Recruiting
          • Relapsing-Remitting Multiple Sclerosis
          • Alexandria, Egypt
          • +1 more
          Jun 14, 2022

          Integrated Digital Solutions in Medical Care of Multiple

          Not yet recruiting
          • Relapsing Remitting Multiple Sclerosis
          • MS Care Platform (icobrain ms and icompanion ms)
          • (no location specified)
          Jul 10, 2023

          Multiple Sclerosis, Relapsing-remitting Multiple Sclerosis Trial in West Orange (GEMS Plus, GEMS)

          Recruiting
          • Multiple Sclerosis
          • Relapsing-remitting Multiple Sclerosis
          • GEMS Plus
          • GEMS
          • West Orange, New Jersey
            Kessler Foundation
          Feb 23, 2023

          Mechanistic Studies of Teriflunomide in RRMS

          Active, not recruiting
          • Relapsing Remitting Multiple Sclerosis
          • Ann Arbor, Michigan
            University of Michigan
          Jul 27, 2022

          Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis Trial in United States (ANK-700, Placebo)

          Recruiting
          • Multiple Sclerosis (MS)
          • Relapsing Remitting Multiple Sclerosis
          • Cullman, Alabama
          • +14 more
          Dec 13, 2022

          Relapsing Remitting Multiple Sclerosis Trial in Glasgow (Clinical assessment)

          Enrolling by invitation
          • Relapsing Remitting Multiple Sclerosis
          • Clinical assessment
          • Glasgow, United Kingdom
            Clinical Research Facility
          Jul 20, 2022

          Multiple Sclerosis, Relapsing-Remitting Trial in Amsterdam (Ocrelizumab)

          Recruiting
          • Multiple Sclerosis, Relapsing-Remitting
          • Amsterdam, Noord-Holland, Netherlands
            Amsterdam UMC, location VU
          Apr 21, 2022

          Biomarkers in Relapsing-Remitting Multiple Sclerosis

          Recruiting
          • Multiple Sclerosis
          • Relapsing Remitting Multiple Sclerosis
          • 1. Clinical testing; 2. Neurophysiological examination (TMS, EMNG); 3. Psychomotor examination; 4. Neuropsychological evaluation; 5. Flow cytometry; 6. ELISA
          • Split, Croatia
            University of Split School of Medicine
          Feb 28, 2022

          Multiple Sclerosis, Relapsing-remitting Multiple Sclerosis Trial in France (Perfusion of treatment Rituximab, Perfusion of

          Not yet recruiting
          • Multiple Sclerosis
          • Relapsing-remitting Multiple Sclerosis
          • Perfusion of treatment Rituximab
          • Perfusion of treatment Ocrelizumab
          • Lyon, Bron, France
          • +22 more
          Mar 6, 2023

          Multiple Sclerosis Trial (In-phase Bilateral Exercises of the upper limbs)

          Not yet recruiting
          • Multiple Sclerosis
          • In-phase Bilateral Exercises of the upper limbs
          • (no location specified)
          May 5, 2022

          Multiple Sclerosis Trial in Denizli (Expanded Disability Status Scale, pulmonary function test, International Physical Activity

          Completed
          • Multiple Sclerosis
          • Expanded Disability Status Scale, pulmonary function test, International Physical Activity Questionnaire - Short Form, 6 minute walk test
          • Denizli, Turkey
            Pamukkale University
          Jan 24, 2023